Drugs / 68Ga-BC1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06717113 | Apr → Dec 2025 overdue | plasma cell myeloma | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-BC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06717113 ↗ |
| Route | Intravenous | “The prepared and quality-controlled 68Ga-BC1 (0.05-0.1 mCi/kg) will be intravenously injected into the patient” NCT06717113 ↗ |